Wednesday, October 22, 2014 Last update: 8:03 PM - Covering Large & Obscure Tech Companies Since 1996

Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014

Companies mentioned in this article: Epizyme, Inc.

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Wednesday, August 13, 2014 at 8:00 a.m. ET to report second quarter 2014 financial results and provide a corporate update.

To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 80954146. The live webcast can be accessed under “Events and Presentations” in the Investor Relations section of the Company’s website at

The archived webcast will be available on the Company’s website beginning approximately two hours after the event.

On Tuesday, August 12, Epizyme Chief Scientific Officer Robert Copeland, Ph.D., will give an oral presentation at the American Society of Hematology (ASH) Meeting on Lymphoma Biology. The presentation will include findings characterizing the activity of EPZ-6438, a small molecule inhibitor of EZH2, in pre-clinical models of non-Hodgkin lymphoma (NHL), both as a single agent and in combination with NHL standards of care. The presentation will also highlight the early clinical experience from an ongoing Phase 1 study of EPZ-6438 (E7438) in patients with advanced malignancies, including NHL.

Slides from the presentation will be available on the Company’s website following the event.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit and connect with us on Twitter at @EpizymeRx.

Copyright © Business Wire 2014

Epizyme, Inc.
Manisha Pai, 617-229-7560
Senior Director, Corporate Communications